BIOLOGICAL TREATMENTS IN ALLERGY: PRESCRIPTION AND MANAGEMENT OF HYPERSENSITIVITY REACTIONS
2 Universidad de Málaga [Málaga] = University of Málaga [Málaga]
3 Vanderbilt University School of Medicine [Nashville]
4 Azienda Ospedaliera Universitaria Integrata of Verona
5 SNUBH - Seoul National University Bundang Hospital
6 Service Pneumologie, Allergologie et Oncologie thoracique [Hôpital Arnaud de Villeneuve - CHU Montpellier]]
7 Centro Médico Docente La Trinidad
8 Children's Mercy Hospital [Kansas City]
9 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
10 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
11 Allergologue
12 UL - Université de Lorraine
13 IMED School of Medicine [Passo Fundo]
14 UNIPV - Università degli Studi di Pavia [Italia] = University of Pavia [Italy] = Université de Pavie [Italie]
15 Hospital Quirónsalud Bizkaia [Bilbao]
16 Hospital CUF Descobertas
17 Sagamihara National Hospital [Kanagawa, Japan]
18 OSU - The Ohio State University [Columbus]
19 Tan Tock Seng Hospital
20 Hospital Sírio-Libanês [São Paulo, Brazil]
- Fonction : Auteur
- PersonId : 933609
- ORCID : 0000-0001-6230-9706
- Fonction : Auteur
- PersonId : 799503
- ORCID : 0000-0003-1837-2980
- Fonction : Auteur
- PersonId : 754222
- IdHAL : pascal-demoly
- ORCID : 0000-0001-7827-7964
- IdRef : 03442959X
- Fonction : Auteur
- PersonId : 987406
- IdHAL : luciana-kase-tanno
- ORCID : 0000-0003-3236-1225
- IdRef : 248787136
Résumé
Background: Allergy is witnessing major advances, in particular with the advent of biological therapies for treating allergic diseases. Given the novelty of these therapeutics, we aimed to explore by a worldwide survey, the prescription and the management of hypersensitivity reactions (HR) of biological agents (BA) in Allergy. Method: We built up an anonymous online questionnaire, sent out by mail and social media and circulated for 40 days. Results: 348 responses were from 59 countries, with a majority from Europe (62.6%). 97% of responders practiced allergy and 48.5%, exclusively so. Allergy was mentioned as a full specialty in 69.5% of cases. 71% of responders confirmed the right of prescription of BA for allergists in their country and 78.4% prescribed BA in their clinical practice. Europe included almost all the allergists who did not have the right of prescribing BA (95.5%), specifically France (91%). The most prescribed BA were Anti IgE (78.1%) and anti IL5 (43.9%). The most declared HR to BA were local reactions (74.1%) followed by anaphylaxis like symptoms (6.8%) and delayed exanthemas (5.1%). Desensitization was considered in 18.9% of cases. These HR were reported in 48.8% of cases. Conclusion: Although BA are now a pillar in the treatment of allergic diseases and allergists are familiar with management of HR associated with BA, their prescription is not authorized for allergists in all countries. BA showed to be generally safe but HR, which may be severe, could occur with a lack of consensus on the management.